Success Metrics

Clinical Success Rate
77.3%

Based on 17 completed trials

Completion Rate
77%(17/22)
Active Trials
0(0%)
Results Posted
6%(1 trials)
Terminated
5(21%)

Phase Distribution

Ph phase_2
12
50%
Ph phase_3
1
4%
Ph early_phase_1
2
8%
Ph phase_1
9
38%

Phase Distribution

11

Early Stage

12

Mid Stage

1

Late Stage

Phase Distribution24 total trials
Early Phase 1First-in-human
2(8.3%)
Phase 1Safety & dosage
9(37.5%)
Phase 2Efficacy & side effects
12(50.0%)
Phase 3Large-scale testing
1(4.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.3%

17 of 22 finished

Non-Completion Rate

22.7%

5 ended early

Currently Active

0

trials recruiting

Total Trials

24

all time

Status Distribution
Completed(17)
Terminated(5)
Other(2)

Detailed Status

Completed17
Terminated5
unknown2

Development Timeline

Analytics

Development Status

Total Trials
24
Active
0
Success Rate
77.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 12 (8.3%)
Phase 19 (37.5%)
Phase 212 (50.0%)
Phase 31 (4.2%)

Trials by Status

unknown28%
completed1771%
terminated521%

Recent Activity

0 active trials
Showing 5 of 24
completedphase_2

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

NCT00019396
completedphase_2

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

NCT00020475
completedearly_phase_1

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

NCT02320305
completedphase_1

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

NCT00470015
completedearly_phase_1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

NCT01748747
View all 24 trials

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT00019396Phase 2

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Completed
NCT00020475Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Completed
NCT02320305Early Phase 1

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Completed
NCT00470015Phase 1

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Completed
NCT01748747Early Phase 1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Completed
NCT01307618Phase 2

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Terminated
NCT00091338Phase 1

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed
NCT00089063Phase 2

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed
NCT00031733Phase 2

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed
NCT00005841Phase 1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated
NCT00006113Phase 2

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated
NCT00025181Phase 1

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Completed
NCT00334776Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed
NCT00010309Phase 1

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Unknown
NCT00037037Phase 1

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Unknown
NCT00002952Phase 1

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Completed
NCT00003792Phase 1

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed
NCT00019214Phase 1

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed
NCT00019721Phase 2

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed
NCT00019994Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
24